Zhuhai Campus, Zunyi Medical University, Jinwan District, Zhuhai, 519041, Guangdong, China.
Pharmaceutical Preparation Section, Guizhou Province People's Hospital, Guiyang, Guizhou, China.
BMC Complement Altern Med. 2018 Apr 5;18(1):122. doi: 10.1186/s12906-018-2189-6.
Crocin (CRO), chlorogenic acid (CGA), geniposide (GEN), and quercetin (QUE) are all natural compounds with anti-obesity properties, in particular, hypolipidemic effects, which have been widely used for the treatment of obesity-related metabolic diseases. However, it is not yet known whether these compounds interact synergistically. Here, we investigated the effects and molecular mechanisms of CRO, CGA, GEN, QUE, and a combination of all four compounds (CCGQ), on lipid accumulation in human hepatoma (HepG2 cells).
The optimal concentration of CRO, CGA, GEN, QUE to stimulate HepG2 cells proliferation was determined using MTT assay. HepG2 cells were pretreated with 10 μmol/L simvastatin, 1 μmol/L CRO, 30 μmol/L CGA, 10 μmol/L GEN, 10 μmol/L QUE, and CCGQ (a combination of 1 μmol/L CRO, 30 μmol/L CGA, 10 μmol/L GEN, and 10 μmol/L QUE) for 24 or 48 h. Oil red O staining and extracellular TC and TG levels were detected. The RT-PCR was used to observe on cholesterol metabolism-related gene expression. Immunocytochemistry and western-blot assayed the 3-hydroxy-3-methylglutaryl-coenzyme (HMGCR) protein expression in HepG2 cells.
Compared to those of control, we demonstrated that treating HepG2 cells for 48 h with CCGQ resulted in a strong synergistic effect, causing a marked decrease in lipid deposition in comparison to individual treatments, in both triglyceride and total cholesterol (CRO, 5.74- and 1.49-folds; CGA, 3.38- and 1.12-folds; GEN, 4.04- and 1.44-folds; QUE, 3.36- and 1.24-folds; simvastatin, 5.49- and 1.83-folds; and CCGQ, 7.75- and 2.20-folds), and Oil red O staining assays. In addition, CCGQ treatment increased ATP-binding cassette transporter (ABCA1), cholesterol 7α-hydroxylase (CYP7A1), and AMP-activated protein kinase 2α (AMPKα2) mRNA expression, while decreasing sterol regulatory element binding protein 2 (SREBP2), and liver X receptor alpha (LXRα) mRNA expression. Notably, CCGQ was more effective in decreasing HMGCR expression than the individual treatments.
The CCGQ combination has potential, both as a complementary therapy for hyperlipemia, and in preventing further obesity-related complications.
藏红花酸(CRO)、绿原酸(CGA)、栀子苷(GEN)和槲皮素(QUE)都是具有抗肥胖特性的天然化合物,特别是具有降血脂作用,已广泛用于治疗与肥胖相关的代谢疾病。然而,目前尚不清楚这些化合物是否具有协同作用。在这里,我们研究了 CRO、CGA、GEN、QUE 以及这四种化合物的组合(CCGQ)对人肝癌(HepG2 细胞)中脂质积累的影响及其分子机制。
用 MTT 法测定 CRO、CGA、GEN、QUE 刺激 HepG2 细胞增殖的最佳浓度。用 10 μmol/L 辛伐他汀、1 μmol/L CRO、30 μmol/L CGA、10 μmol/L GEN、10 μmol/L QUE 和 CCGQ(1 μmol/L CRO、30 μmol/L CGA、10 μmol/L GEN 和 10 μmol/L QUE 的组合)预处理 HepG2 细胞 24 或 48 h。油红 O 染色和细胞外 TC 和 TG 水平检测。用 RT-PCR 观察胆固醇代谢相关基因的表达。免疫细胞化学和 Western-blot 检测 HepG2 细胞中 3-羟-3-甲基戊二酰辅酶 A(HMGCR)蛋白的表达。
与对照组相比,我们发现 CCGQ 处理 HepG2 细胞 48 h 后,与单独处理相比,甘油三酯和总胆固醇的脂质沉积明显减少(CRO,5.74-和 1.49-倍;CGA,3.38-和 1.12-倍;GEN,4.04-和 1.44-倍;QUE,3.36-和 1.24-倍;辛伐他汀,5.49-和 1.83-倍;CCGQ,7.75-和 2.20-倍),油红 O 染色试验也如此。此外,CCGQ 处理增加了 ATP 结合盒转运体(ABCA1)、胆固醇 7α-羟化酶(CYP7A1)和 AMP 激活蛋白激酶 2α(AMPKα2)mRNA 的表达,同时降低了固醇调节元件结合蛋白 2(SREBP2)和肝 X 受体α(LXRα)mRNA 的表达。值得注意的是,CCGQ 降低 HMGCR 表达的效果优于单独用药。
CCGQ 联合用药具有互补治疗高脂血症和预防进一步肥胖相关并发症的潜力。